该研究的两个主要终点是pCR率(ypT0/Tis,ypN0)和无事件生存(EFS)期,此次会议主要报告其中一个主要研究终点:pCR率。 Keynote756研究结果分析 Keynote756研究纳入了共1278例患者,并随机分配到帕博利珠单抗+新辅助化疗组(n=635)或安慰剂+新辅...
Join BritCham, UN and KPMG to hear from keynote speaker Siddharth Chatterjee, UN Resident Coordinator in China.
KEYNOTE-189研究中帕博利珠单抗联合化疗一线治疗晚期NSCLC患者的ORR为()。A.39.1%B.23.2%C.18.9%D.47.6%的答案是什么.用刷刷题APP,拍照搜索答疑.刷刷题(shuashuati.com)是专业的大学职业搜题找答案,刷题练习的工具.一键将文档转化为在线题库手机刷题,以提高学习效率,是学
Keynote：超越 PPT 的苹果商业幻灯片(第 2 版)思维导图 {"code":"InvalidRange","message":"Therequestedrangecannotbesatisfied.","requestId":"67c5829b-0399-417a-9f6a-ee172112082a"}
According to Ix, the keynote speaker and recipient of the NKF’s 2020 Shaul G. Massry Award, noninvasive kidney tubule health assessment might bring markers to predict loss of kidney function independent of glomerular markers, might predict chroni...
在早期NSCLC中,研究者开展了PD-1抑制剂帕博利珠单抗对比安慰剂术后辅助治疗IB-IIIA期(AJCC 7th TNM)NSCLC的KEYNOTE-091研究。 KEYNOTE-091是一项随机对照、三盲、III期临床试验,主要评估帕博利珠单抗 vs 安慰剂联合或不联合辅助化疗作为手术切除(肺叶...
Keynote Speaker Introduction Dr. Petra E. Todd EDMUND J. AND LOUISE W. KAHN TERM PROFESSOR OF ECONOMICS Chair, Department of Economics, University of Pennsylvania Professor Todd is also a Research Associate of Penn’s Population Studies Center, NBER, and I...